Eupraxia Pharmaceuticals Inc. (EPRX)
Eupraxia Pharmaceuticals Inc. (EPRX) is a Healthcare stock tracked by StreetAlpha. It last closed at $6.62 on Nov 17, down 9.81% on the day. The average 12-month price target from 3 analysts is $15.67 (+136.7% from the last close), with a high of $17.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $562K, the largest $358K.
Key Stats
Fiscal 2025Not reported for this period.
From EPRX's SEC filings, latest 40-F for the period ending Dec 31, 2025 (filed Mar 13). Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on EPRX in the past 90 days. The average target is $15.67, with a high of $17.00 and a low of $14.00, compared with the last close of $6.62.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 11 | HC Wainwright & Co. | Target raised | Buy | $11 → $16 |
| Nov 9 | RBC Capital | Initiated | Buy | $14 |
| Oct 1 | HC Wainwright & Co. | Reiterated | Buy | $11 |
| Sep 24 | Wedbush | Initiated | Buy | $17 |
| Jun 26 | Oppenheimer | Initiated | Buy | $17 |
Technical Analysis
The stock is 9% below its 20 day and 15% below its 50 day average. It is 9% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the swing low (Oct 14) at $6.42, and the nearest resistance the swing high (Jul 31) at $6.74.
| RSI (14) | 42.23 | Middle of its range | Neutral |
| MACD | 0.01 | Above its signal line | Bullish |
| Stochastic | 48.9 | Middle of its range | Neutral |
| ADX (14) | 14.4 | No clear trend | |
| Williams %R | -85.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -65.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −3.8% | Change over 10 sessions | Bearish |
| ATR (14) | $0.56 | Typical daily range, 8.4% of price |
| RSI (14) | 46.07 | Middle of its range | Neutral |
| MACD | 0.06 | Below its signal line | Bearish |
| Stochastic | 31.6 | Middle of its range | Neutral |
| ADX (14) | 16.4 | No clear trend | |
| Williams %R | -89.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -4.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −21.4% | Change over 10 sessions | Bearish |
| ATR (14) | $1.10 | Typical daily range, 16.6% of price |
What happened before
See how EPRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in EPRX in the last 90 days.
Dark Pool
30DEPRX Institutional Ownership
Full report →- ●32 buying vs 30 selling
- ▲Shares held by funds +21.4%
- ▲Funds holding +2
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 70 | 68 | +2.9% |
| In funds' top 10 | 2 | 0 | – |
| Held by funds | – | – | – |
| New / increased | 11 / 21 | 16 / 21 | −13.5% |
| Reduced / sold out | 21 / 9 | 18 / 6 | +25.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EPRX is in one of them and how their past EPRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered EPRX in an article yet. Here's the latest on the wider market.


